Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
作者信息
Montillo Marco, Tedeschi Alessandra, Gaidano Gianluca, Coscia Marta, Petrizzi Valeria Belsito, Orlandi Ester, Cascavilla Nicola, Ghia Paolo, Motta Marina, Gallamini Andrea, Frustaci Anna Maria, Rossi Davide, De Paoli Lorenzo, Nichelatti Michele, Morra Enrica, Massaia Massimo
机构信息
Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milano
Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milano.
出版信息
Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.
Abstract
摘要
相似文献
1
Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.苯达莫司汀与皮下注射阿仑单抗联合使用是复发/难治性慢性淋巴细胞白血病患者的一种有效治疗方法。
Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.
2
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.苯达莫司汀治疗慢性淋巴细胞白血病：结果与未来展望
Semin Oncol. 2002 Aug;29(4 Suppl 13):19-22. doi: 10.1053/sonc.2002.34875.
3
Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.苯达莫司汀单药治疗晚期难治性慢性淋巴细胞白血病。
J Cancer Res Clin Oncol. 2001 Jan;127(1):48-54. doi: 10.1007/s004320000180.
4
Bendamustine for treatment of chronic lymphocytic leukemia.苯达莫司汀治疗慢性淋巴细胞白血病。
Expert Opin Pharmacother. 2012 Jul;13(10):1495-505. doi: 10.1517/14656566.2012.693163. Epub 2012 Jun 5.
5
Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?苯达莫司汀治疗慢性淋巴细胞白血病：如今的共识会多快成为明日的记忆？
Leuk Res. 2014 Nov;38(11):1267-8. doi: 10.1016/j.leukres.2014.08.003. Epub 2014 Aug 11.
6
Huge kidneys in a patient with chronic lymphocytic leukaemia.一名慢性淋巴细胞白血病患者的巨大肾脏。
Br J Haematol. 2015 Feb;168(4):470. doi: 10.1111/bjh.13218. Epub 2014 Nov 11.
7
Bendamustine.苯达莫司汀
Nat Rev Drug Discov. 2008 Jun;7(6):473-4. doi: 10.1038/nrd2596.
8
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.西班牙使用苯达莫司汀治疗非霍奇金淋巴瘤和慢性淋巴细胞白血病的临床经验。
Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024. Epub 2011 Dec 7.
9
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.一项Ⅰ期研究显示，每周皮下给予递增剂量的阿仑单抗联合利妥昔单抗治疗复发的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。
Haematologica. 2013 Jun;98(6):964-70. doi: 10.3324/haematol.2013.086207. Epub 2013 May 3.
10
Bendamustine's emerging role in the management of lymphoid malignancies.苯达莫司汀在淋巴恶性肿瘤治疗中的新作用。
Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004.
引用本文的文献
1
Advances in targeted therapy for malignant lymphoma.恶性淋巴瘤靶向治疗的进展。
Signal Transduct Target Ther. 2020 Mar 6;5(1):15. doi: 10.1038/s41392-020-0113-2.
本文引用的文献
1
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.苯达莫司汀联合奥法妥木单抗治疗复发/难治性慢性淋巴细胞白血病：一项 GIMEMA 多中心 II 期试验。
Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13.
2
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.在接受阿仑单抗治疗的氟达拉滨难治性 CLL 患者中 NOTCH1、SF3B1 和 TP53 突变：GCLLSG 的 CLL2H 试验结果。
Blood. 2013 Aug 15;122(7):1266-70. doi: 10.1182/blood-2013-03-488197. Epub 2013 Jul 2.
3
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.苯达莫司汀联合利妥昔单抗治疗初治慢性淋巴细胞白血病患者：德国慢性淋巴细胞白血病研究组的一项多中心 II 期试验。
J Clin Oncol. 2012 Sep 10;30(26):3209-16. doi: 10.1200/JCO.2011.39.2688. Epub 2012 Aug 6.
4
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.氟达拉滨和环磷酰胺联合阿仑单抗治疗原发性高危、复发或难治性慢性淋巴细胞白血病患者。
Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15.
5
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.在一项随机 3 期临床试验中，在未经治疗的慢性淋巴细胞白血病患者中，用氟达拉滨和环磷酰胺联合阿仑单抗治疗后的超额死亡率。
Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14.
6
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.氟达拉滨联合阿仑单抗与氟达拉滨单药治疗既往治疗的慢性淋巴细胞白血病患者：一项随机 3 期试验。
Lancet Oncol. 2011 Dec;12(13):1204-13. doi: 10.1016/S1470-2045(11)70242-X. Epub 2011 Oct 10.
7
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.苯达莫司汀联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病患者：德国慢性淋巴细胞白血病研究组的一项多中心 II 期试验。
J Clin Oncol. 2011 Sep 10;29(26):3559-66. doi: 10.1200/JCO.2010.33.8061. Epub 2011 Aug 15.
8
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和阿仑单抗治疗复发/难治性 B 细胞慢性淋巴细胞白血病患者的开放性、先导研究。
Blood. 2011 Oct 13;118(15):4079-85. doi: 10.1182/blood-2011-05-351833. Epub 2011 Jul 19.
9
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.氟达拉滨、环磷酰胺和利妥昔单抗化疗免疫治疗是治疗 CLL 复发患者的非常有效方法。
Blood. 2011 Mar 17;117(11):3016-24. doi: 10.1182/blood-2010-08-304683. Epub 2011 Jan 18.
10
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.利妥昔单抗联合氟达拉滨和环磷酰胺相较于氟达拉滨和环磷酰胺单药治疗可延长先前治疗的慢性淋巴细胞白血病患者的无进展生存期。
J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1.
Zotero 插件